Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Cardiovascular/Ventricular Tachycardia

Ventricular Tachycardia

15

Pipeline Programs↗

25

Active Trials↗

10

Companies Involved↗

Ventricular Tachycardia is an emerging landscape with 15 programs across 10 companies.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

36/100

Mech. Concentration

20/100

Completion Rate

56/100

Attrition Rate

21/100

Pipeline

Programs by Phase

Preclinical11

Sotalol

Legacy Health System

Fentanyl

Cephalon

Versed

Emory University

Guideline Directed Medical Therapy

IRCCS Policlinico S. Donato

Anti-Arrhythmic Drugs

C. R. Bard

Phase 11

SGT-501

Solid Biosciences Inc.

Phase 23

Venous Ethanol

The Methodist Hospital Research Institute

CRD-4730

Cardurion Pharmaceuticals, Inc.

AGP100

Agiana Pharmaceuticals

Phase 3

No programs

Approved

No programs

Analysis

Trial Status

52

clinical trials

Recruiting19 · 37%

Completed14 · 27%

Terminated8 · 15%

Not yet recruiting3 · 6%

Active, not recruiting3 · 6%

Withdrawn3 · 6%

Other2 · 4%

Clinical Trials

Trial Activity

52 trials

Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia

Recruiting·MMedtronic Cardiac Ablation Solutions·Preclinical·NCT07585968·260 enrolled

A Phase 1b, Multicenter, Open-Label, Dose Finding Study to Investigate the Safety and Tolerability of a Single Intravenous Dose of SGT-501 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia

Recruiting·SSolid Biosciences Inc.·Phase 1·NCT07148089·18 enrolled

Evaluation of the DuoVT PFA System for Ventricular Tachycardia

Recruiting·AAbbott Medical Devices·Preclinical·NCT07706712·50 enrolled

Cryoablation for Monomorphic Ventricular Tachycardia IDE Study

Recruiting·AAdagio Medical·Preclinical·NCT07650032·100 enrolled

Dynamic Voltage Mapping to Personalise the Ventricular Tachycardia Substrate

Recruiting·LLiverpool Heart and Chest Hospital NHS Foundation Trust·Preclinical·NCT07573579·40 enrolled

Catheter Ablation Versus Radio-Ablation for Ventricular Tachycardia: a Randomized Controlled Trial

Recruiting·OOttawa Heart Institute Research Corporation·Phase 3·NCT05047198·244 enrolled

Segmental Substrate Isolation for the Treatment of Ventricular Tachycardia in Patients With Structural Heart Disease

Recruiting·NNew York Medical College·N/A·NCT07814079·30 enrolled

Pulse Field Ablation for Post-Infarction Ventricular Tachycardia: the ASCEND Pilot Study

Recruiting·—·Preclinical·NCT06891456·40 enrolled

Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia

Recruiting·MMedtronic Cardiac Ablation Solutions·Preclinical·NCT06703489·60 enrolled

Dose Escalation for Stereotactic Cardiac Radiation Therapy of Recurrent Ventricular Tachyarrhythmia - a Multi Center, Phase II Clinical Trial

Recruiting·UUniversity of Zurich·Phase 1·NCT05594368·15 enrolled

Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex Ablation - an International Multicenter Collaborative Study Group

Recruiting·UUniversity Hospital, Basel, Switzerland·N/A·NCT07777744·15,000 enrolled

Using Non-Invasive Mapping To Eliminate Structural Heart Disease Ventricular Tachycardia: a UK Randomised Controlled Trial

Recruiting·UUniversity of Warwick·Preclinical·NCT07759427·110 enrolled

Ventricular Tachycardia：A Registry Study

Recruiting·BBeijing Anzhen Hospital·N/A·NCT07149701·1,000 enrolled

Venous Ethanol for Ischemic Left Ventricular Tachycardia

Recruiting·TThe Methodist Hospital Research Institute·Phase 2·NCT05511246·156 enrolled

A Phase 2, Double-Blind, Repeat-Dose, Placebo-Controlled Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CRD-4730 In Participants With Catecholaminergic Polymorphic Ventricular Tachycardia

Recruiting·CCardurion Pharmaceuticals, Inc.·Phase 2·NCT06658899·12 enrolled

Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)